Congenital amegakaryocytic thrombocytopenia with and without clonal evolution to myelodysplastic syndrome: peripheral blood stem cell transplantation outcomes in a pediatric single-center case series
Year: 2026
Type: article
Study design: Case Report
Abstract: Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only cure for congenital amegakaryocytic thrombocytopenia (CAMT). However, transplant outcomes for patients progressing to myelodysplastic syndrome (MDS) with monosomy 7 remain largely unreported. Methods: We retrospectively analyzed five pediatric CAMT patients undergoing peripheral blood stem cell (PBSC) transplantation. All received uniform non-TBI myeloablative conditioning (busulfan, cyclophosphamide, rATG) with cyclosporine/methotrexate GVHD prophylaxis. Two had progressed to MDS with monosomy 7. Results: All five patients achieved rapid engraftment (median neutrophil 12 days, platelet 14 days) with donor chimerism > 99% at the last assessment and no primary graft failure. At a 3-year median follow-up, 80% (4/5) remain alive with sustained transfusion independence. The single mortality occurred in a patient with MDS with monosomy 7, who succumbed to grade IV hemorrhagic cystitis, in the setting of grade IV acute GVHD, at two months. Conclusion: In this small series, non-TBI myeloablative PBSC transplantation was associated with rapid engraftment and durable hematopoietic reconstitution in CAMT without MDS. In patients with pre-existing MDS/monosomy 7, outcomes were heterogeneous (one survivor, one death); given the small sample and concurrent risk factors, an independent effect of MDS/monosomy 7 cannot be established. These observations underscore the importance of early genetic diagnosis and timely HSCT referral.
Source: Annals of Hematology
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: congenital amegakaryocytic thrombocytopenia, myelodysplastic syndrome, monosomy 7, clonal evolution, peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation, pediatric patients, myeloablative conditioning, graft-versus-host disease, engraftment, transfusion independence, hemorrhagic cystitis
Open Access status: gold
Estimated APC paid: $4,590
OpenAlex ID: W7234383856
